Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Bahaa Salem is active.

Publication


Featured researches published by Bahaa Salem.


Journal of Medicinal Chemistry | 2017

Structure-Based Library Design and Fragment Screening for the Identification of Reversible Complement Factor D Protease Inhibitors

Anna Vulpetti; Stefan Andreas Randl; Simon Rüdisser; Nils Ostermann; Paul Erbel; Aengus Mac Sweeney; Thomas Zoller; Bahaa Salem; Bernd Gerhartz; Frederic Cumin; Ulrich Hommel; Claudio Dalvit; Edwige Liliane Jeanne Lorthiois; Jürgen Maibaum

Chronic dysregulation of alternative complement pathway activation has been associated with diverse clinical disorders including age-related macular degeneration and paroxysmal nocturnal hemoglobinurea. Factor D is a trypsin-like serine protease with a narrow specificity for arginine in the P1 position, which catalyzes the first enzymatic reaction of the amplification loop of the alternative pathway. In this article, we describe two hit finding approaches leading to the discovery of new chemical matter for this pivotal protease of the complement system: in silico active site mapping for hot spot identification to guide rational structure-based design and NMR screening of focused and diverse fragment libraries. The wealth of information gathered by these complementary approaches enabled the identification of ligands binding to different subpockets of the latent Factor D conformation and was instrumental for understanding the binding requirements for the generation of the first known potent noncovalent reversible Factor D inhibitors.


Blood | 2014

ABL001, a Potent Allosteric Inhibitor of BCR-ABL, Prevents Emergence of Resistant Disease When Administered in Combination with Nilotinib in an in Vivo Murine Model of Chronic Myeloid Leukemia

Andrew Wylie; Joseph Schoepfer; Giuliano Berellini; Hongbo Cai; Giorgio Caravatti; Simona Cotesta; Stephanie Dodd; Jerry Donovan; Bernhard Erb; Pascal Furet; Geeti Gangal; Robert Martin Grotzfeld; Quamrul Hassan; Tami Hood; Varsha Iyer; Sandra Jacob; Wolfgang Jahnke; Franco Lombardo; Alice Loo; Paul W. Manley; Andreas Marzinzik; Michael Palmer; Xavier Francois Andre Pelle; Bahaa Salem; Sreenath V. Sharma; Sanjeev Thohan; Suzanne Zhu; Nicholas Keen; Lilli Petruzzelli; K. Gary Vanasse


Archive | 2013

Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1

Stephanie Dodd; Pascal Furet; Robert Martin Grotzfeld; Darryl Brynley Jones; Paul W. Manley; Andreas Marzinzik; Xavier Francois Andre Pelle; Bahaa Salem; Joseph Schoepfer


Archive | 2013

Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1

Pascal Furet; Robert Martin Grotzfeld; Wolfgang Jahnke; Darryl Brynley Jones; Paul W. Manley; Andreas Marzinzik; Saliha Moussaoui; Xavier Francois Andre Pelle; Bahaa Salem; Joseph Schoepfer


Journal of Medicinal Chemistry | 2018

Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1.

Joseph Schoepfer; Wolfgang Jahnke; Giuliano Berellini; Silvia Buonamici; Simona Cotesta; Sandra W. Cowan-Jacob; Stephanie Dodd; Peter Drueckes; Doriano Fabbro; Tobias Gabriel; Jean-Marc Groell; Robert Martin Grotzfeld; Asm Quamrul Hassan; Christelle Henry; Varsha Iyer; Darryl Brynley Jones; Franco Lombardo; Alice Loo; Paul W. Manley; Xavier Francois Andre Pelle; Gabriele Rummel; Bahaa Salem; Markus Warmuth; Andrew Wylie; Thomas Zoller; Andreas Marzinzik; Pascal Furet


Archive | 2017

derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1

Andreas Marzinzik; Bahaa Salem; Darryl Brynley Jones; Joseph Schoepfer; Pascal Furet; Paul W. Manley; Robert Martin Grotzfeld; Stephanie Dodd; Wolfgang Jahnke; Xavier Francois Andre Pelle


Archive | 2017

compostos e composições para inibir a atividade de abl1, abl2 e bcr-abl1

Andreas Marzinzik; Bahaa Salem; Darryl Brynley Jones; Joseph Schoepfer; Pascal Furet; Paul W. Manley; Robert Martin Grotzfeld; Saliha Moussaoui; Wolfgang Jahnke; Xavier Francois Andre Pelle


Archive | 2017

Thiazole or imidazole substituted pyrimidine, pyridine and pyrazine amide derivatives and related compounds as abl1, abl2 and bcr-abl1 inhibitors for the treatment of cancer, specific viral infections and specific cns disorders

Pascal Furet; Robert Martin Grotzfeld; Darryl Brynley Jones; Paul W. Manley; Andreas Marzinzik; Saliha Moussaoui; Xavier Francois Andre Pelle; Bahaa Salem; Joseph Schoepfer; Wolfgang Jahnke


Archive | 2015

Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.

Pascal Furet; Stephanie Dodd; Robert Martin Grotzfeld; Darryl Brynley Jones; Paul W. Manley; Andreas Marzinzik; Xavier Francois Andre Pelle; Bahaa Salem; Joseph Schoepfer; Wolfgang Jahnke


Archive | 2013

COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE LA ABL1, ABL2 Y BCR-ABL1

Stephanie Dodd; Pascal Furet; Robert Martin Grotzfeld; Darryl Brynley Jones; Paul W. Manley; Andreas Marzinzik; Xavier Francois Andre Pelle; Bahaa Salem; Joseph Schoepfer

Collaboration


Dive into the Bahaa Salem's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Robert Martin Grotzfeld

Massachusetts Institute of Technology

View shared research outputs
Top Co-Authors

Avatar

Robert Martin Grotzfeld

Massachusetts Institute of Technology

View shared research outputs
Researchain Logo
Decentralizing Knowledge